What is Amphastar Pharmaceuticals's baqsimi — revenue?

Amphastar Pharmaceuticals (AMPH) reported baqsimi — revenue of $100K in Q2 2026.

What does baqsimi — revenue mean?

This metric measures the total gross income generated from the sale of Baqsimi products to customers, including wholesalers and clinical settings. It serves as a primary indicator of the product's market adoption, pricing power, and overall commercial success within the company's portfolio. Growth in this metric is a key driver of the company's top-line performance and segment-specific profitability.

Amphastar Pharmaceuticals (AMPH) Baqsimi — Revenue

Screener

Other product segments

Primatenemist

$24.17M+2.9%

Similar metrics at other companies

LENOther revenues — Revenue

$331.4M-6.8%

PRGOther Revenues — Revenue

$21.62M+165%

BDLOther Revenues — Revenue

$88K+27.5%

AEPCommercial Revenues — Revenue

$1.21B+15.4%

EQIXRecurring revenues — Revenue

$2.38B+10.9%

GCTProduct revenues — Revenue

$290.82M+28.9%

Other financials

Income statement

See full

Revenue$183.9M+5.4%

Gross profit$93.5M+8.1%

Operating income$39.7M-5.8%

Net income$30.3M-2.2%

EPS (diluted)$0.67+4.7%

Balance sheet

See full

Cash & equivalents$223.6M+19.1%

Total debt$688.5M+5.0%

Total equity$445.5M—

Total assets$1.7B+8.0%

Cash flow

See full

Operating cash flow$51.3M+44.2%

CapEx$8.6M-18.7%

Free cash flow$42.7M+70.7%

Valuation

See full

Market cap$916.25M-28.0%

Enterprise value$1.38B-20.6%

P/E11.7×+2.2×

P/S1.3×-0.5×

Profitability

See full

Gross margin47.7%-2.2pp

Operating margin15.7%-9.5pp

Net margin10.8%-7.9pp

FCF margin20.9%+5.4pp

Returns & leverage

See full

Return on equity14.7%—

Debt / equity0.2×—

Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 4:50 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001297184-26-000047

During the three and six months ended June 30, 2026, the Company recognized $0.1 million of revenue from the distribution agreement with Chengong. As of June 30, 2026, the Company did not have any receivables from Chengong.

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's baqsimi — revenue?: Amphastar Pharmaceuticals (AMPH) reported baqsimi — revenue of $100K in Q2 2026.
What does baqsimi — revenue mean?: This metric measures the total gross income generated from the sale of Baqsimi products to customers, including wholesalers and clinical settings. It serves as a primary indicator of the product's market adoption, pricing power, and overall commercial success within the company's portfolio. Growth in this metric is a key driver of the company's top-line performance and segment-specific profitability.